China’s growing role in pharmaceutical supply chains raises serious concerns. Recent reports of GLP-1 ingredients produced in bug-infested, mold-covered facilities underlines the risks of relying on a system with inadequate oversight. American patients should not pay the price of U.S. companies being dependent on Chinese drug manufacturing.